New injectable filler aims to quench thirsty skin

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Subject Informed consent form (ICF) signed; 2. Female and male Subjects aged 18-70 years; 3. Subjects desiring improvement of skin hydration in maximum 1 area of the face or desiring improvement of skin hydration of neck or décolleté. 4. Healthy skin; 5. Willingness to discontinue all dermatological treatment and procedures during the study; 6. Willingness to follow all study procedures, including attending all site visits, tests and examinations; 7. Agreeing to present at each study visit without face/neck/décolleté cosmetics; 8. Accepting to not change their habits regarding food, physical activity, face/neck/décolleté cosmetics and cleansing products; 9. Willingness to follow indications to avoid make-up in the 12 hours following the injection treatment and to avoid any prolonged exposure to the sun, UV rays and temperatures below 0°C, as well as any sauna or hammam sessions at least until the wheals have been fully reabsorbed; 10. Skin phototype I-IV according to Fitzpatrick's classification. Exclusion Criteria: 1. Other - different - clinical conditions of the skin (i.e. rosacea, psoriasis, vitiligo, active eczema, severe scleroderma, severe acne and diagnosticated cancer with/without ongoing antitumor therapy); 2. Infectious or inflammatory processes near the area of intervention; 3. Presence of cutaneous disease on the tested area, as malformations and recurrent facial/labial herpes; 4. Presence of tendon, bone or muscular implants near the area of intervention; 5. Ongoing cutaneous allergies; 6. Allergy or contraindications to device components; 7. Concomitant intake of anticoagulant or antiplatelet medications; 8. Subjects who have not followed a washout period of 2 weeks from topical corticosteroids, antibiotics, benzoyl-peroxide, azelaic acid, hydroxy acids, topical retinoids; 9. Immune system illnesses/disease; 10. Uncontrolled diabetes mellitus or uncontrolled systemic diseases (endocrine, hepatic renal, cardiac, pulmonary, neurological disorder); 11. Treatment with substances which act on blood fluidity (eg. Aspirin, NSAIDs, Vitamin E), or drugs able to influence the test results in the investigator opinion, within 5 days prior to study inclusion; 12. Known drug and/or alcohol abuse; 13. Mental incapacity that precludes adequate understanding or cooperation; 14. Any previous permanent and non-permanent cutaneous treatment for aesthetic correction (biomaterial implant, lifting, laser, botulinum toxin injections, chemical peeling, fillers) of the treated area within 6 months prior to study inclusion; 15. Pregnancy or breastfeeding; 16. Participation in another investigational study within 1 month prior to study inclusion.